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Abstract
In this paper, we propose a new semi-parametric modeling strategy for heterogeneous treat-
ment effect estimation and individualized treatment selection, which are two major goals in
personalized medicine, with a large number of baseline covariates. We achieve the first goal
through estimating a covariate-specific treatment effect (CSTE) curve modeled as an unknown
function of a weighted linear combination of all baseline covariates. The weight or the coefficient
for each covariate is estimated by fitting a sparse semi-parametric logistic single-index coefficient
model. The CSTE curve is estimated by a spline-backfitted kernel procedure, which enables us
to further construct a simultaneous confidence band (SCB) for the CSTE curve under a desired
confidence level. Based on the SCB, we find the subgroups of patients that benefit from each
treatment, so that we can make individualized treatment selection. The proposed method is
quite flexible to depict both local and global associations between the treatment and baseline co-
variates, and thus is robust against model mis-specification in the presence of high-dimensional
covariates. We also establish the theoretical properties of our proposed procedure. They provide
a sound basis for conducting statistical inference in making individualized treatment decisions.
Our proposed method is further illustrated by simulation studies and analysis of a real data
example.
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1 Introduction
Personalized medicine has been a focal area of medical research in recent years, as it takes individual
variability into account for treatment selection. Most traditional clinical trials are designed to
investigate the overall significance of treatment for the entire population, but heterogeneity of
treatment effects indeed exist in subgroups of patients (Wang et al., 2007). For instance, Keller
et al. (2000) compared two treatment regimens for chronic depression based on a 12-week study.
They found that the combination of two treatments overall had a significant advantage over a
single treatment, but it was not effective on a certain group of patients. On one hand, individual
characteristics should be considered in a treatment decision, especially when there are several
treatment options available. On the other band, it is challenging to identify useful information
from the vast amounts of personal medical records in order to make accurate treatment decisions.
The success of personalized medicine crucially depends on the development of accurate and
reliable statistical tools for estimating the optimal treatment regime given the data collected from
clinical trials or observational studies (Kosorok and Laber, 2019). Such tools are important for doc-
tors to make useful personalized recommendations for disease screening, prevention, and treatment.
As such, various statistical methods have been proposed in this direction. Song and Pepe (2004)
proposed a selection impact curve to perform treatment selection based on a single continuous-scale
covariate. The curve divides the entire population into two groups, one of which is more likely to
benefit from the new treatment than the other one. However, this method does not provide an
individual-level decision rule. Bonetti and Gelber (2004) developed a pattern plot of heterogeneous
treatment effects using an improved subgroup-based method, which displays the patterns of treat-
ment effects across overlapping intervals of the covariates. This method requires a large sample
size (often greater than 500) to have a good performance (Bonetti et al., 2000). As a remedy,
Bonetti et al. (2009) proposed an alternative permutation-based inference method, which requires
to specify the number of patients per subpopulation and the largest number of patients in common
among neighbor subpopulations.
Alternatively, researchers rely on non- and semi-parametric modelling methods that provide
a flexible way for investigating heterogeneous treatment effects and subject-specific treatment se-
lection. Cai et al. (2011) proposed a two-stage estimation procedure, by which they estimate the
individualized treatment differences at the first stage and the average treatment difference for each
subgroup at the second stage. The performance of this procedure would depend on the adequacy
of the first stage. Zhou and Ma (2012) proposed a biomarker adjusted treatment effect curve to
assess clinical utility for time-to-event data, and Ma and Zhou (2014) developed a covariate-specific
treatment effect (CSTE) curve with continuous responses. Han et al. (2017) adjusted the CSTE
curve for binary responses.
Most existing methods estimate the optimal treatment regime based on the conditional mean of
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the potential outcome. Thus, it is crucial to find a reliable outcome model, which specifies how the
outcome depends on the treatment and the covariates as well as their interactions. The effects from
the interactions lead to heterogeneous treatment effects. It is often difficult to specify the outcome
model in a completely parametric way, as we often lack sufficient knowledge on how exactly the
treatment affects the outcome given the observed baseline covariates. Clearly, a misspecified out-
come model can lead to a biased estimator of the optimal treatment regime. Therefore, using non-
and semi- parametric methods to approximate the outcome model becomes especially appealing
in this context. Most existing methods (Cai et al., 2011; Zhang et al., 2012; Zhou and Ma, 2012;
Lu et al., 2013; Ma and Zhou, 2014; Laber and Staicu, 2017) are developed for the cases with
low-dimensional covariates. However, recent advances in modern technologies enable researchers to
acquire a large number of baseline characteristics such as genetic variables. It is often difficult to
pre-determine which covariates should be included for treatment effect estimation and treatment
selection before fitting the outcome model. To this end, it is desirable to develop new methods
that can estimate the outcome model in a flexible way as well as selecting important variables si-
multaneously. Moreover, the resulting estimators from the method should be supported by reliable
theoretical properties in order to conduct causal inference.
To achieve the above goals, we present a generalization of the CSTE curve suitable for high
dimensional baseline covariates. The CSTE curve represents the predictive ability of covariates in
evaluating whether a patient responds better to one treatment over another. It has two attractive
features. First, it depicts the treatment effect on the outcome as a function of covariates, so that
we can investigate the heterogeneous treatment effects through estimating the unknown function.
The CSTE curve functions similarly to the receiver operating characteristic curve which is used for
assessing the diagnostic ability of biomarkers. Second, it can visually represent the magnitude of
the predictive ability of a set of covariates. To exploit the information in all covariates, one simple
but effective way is to consider a weighted linear combination of all covariates as a predictor.
This derived predictor is called index variable. The weights, which are estimated from the data,
represent how important the corresponding covariates are for the prediction of the outcome. For
flexibility, we model the CSTE curve as an unknown function of the index variable. This proposed
model is capable of capturing high-order nonlinear interaction effects from the treatment and the
covariates for complex data. It can also be applied to study the case where interaction effects
of individual covariates are weak but those of combined covariates are strong. It is worth noting
that estimation of the weights for the index variable is challenging as we are dealing with high-
dimensional unknown parameters resided in unknown functions. One simple way is to use weights
from performing the principal component analysis on the covariates. These estimated weights do
not reflect how important each covariate is for prediction of the outcome. Therefore, we propose
a concave penalized method to estimate the weights or the coefficients in the index variable and
select variables simultaneously by fitting a sparse semi-parametric logistic single-index coefficient
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model. Our proposed model is motivated by the logistic varying-coefficient model considered in
Han et al. (2017) for treatment selection with one covariate, and it meets the immediate needs from
modern biomedical studies which often have a large number of baseline covariates. After obtaining
the estimates of the coefficients, we propose a spline-backfitted kernel procedure for estimating the
unknown CSTE curve. This method enables us to construct a simultaneous confidence band (SCB)
for the CSTE curve under a desired confidence level. Based on the SCB, we find the subgroups of
patients that benefit from each treatment. The proposed sparse single-index coefficient functions
are flexible enough to depict both local and global associations between the treatment and baseline
covariates, and thus are robust against model mis-specification in the presence of high-dimensional
covariates.
The rest of the paper is organized as follows. In Section 2, we introduce the CSTE curve and the
proposed semi-parametric logistic single-index coefficient model. Section 3 presents the estimation
procedure and the asymptotic properties of the proposed estimators. Section 4 illustrates the
application of the CSTE curves and the SCBs for treatment selection. In Section 5 we evaluate the
finite sample properties of the proposed method via simulation studies, while Section 6 illustrates
the usefulness of the proposed method through the analysis of a real data example. A discussion
is given in Section 7. All technical proofs are relegated to the on-line Supplemental Materials.
2 Methodology
We consider a sample of n subjects, a binary treatment, denoted by Zi = 1 if the subject i is
assigned to treatment and Zi = 0 otherwise, a p-dimensional vector of covariates, denoted by Xi,
and binary-valued outcomes, denoted by Yi. Let
(
Yi, Zi, X
>
i
)
, i = 1, ..., n, be independent and
identically distributed (i.i.d.) samples from
(
Y, Z,X>
)
. Our goal is to select the optimal treatment
by using the observed data. Following the Neyman-Rubin counterfactual framework of causality, we
let Y (1) and Y (0) denote the potential outcomes correspondingly to Z = 1 and Z = 0, respectively.
Since each unit receives only one treatment, i.e., either Y (0) or Y (1) is observed, but not both.
Under the stable unit treatment value assumption, we have that Y ≡ ZY (1) + (1 − Z)Y (0). The
goal is to study the conditional expectation of Y given a set of covariates X. Following Han
et al. (2017), we suggest a varying coefficient model for the covariate-specific treatment effect curve
(termed CSTE) with high-dimensional covariates. It has the following form:
CSTE(X) = logit(E(Y (1) = 1|X))− logit(E(Y (0) = 1|X)),
where logit(u) = log(u)−log(1−u). We make the unconfoundedness assumption (Y (0), Y (1))⊥Z|X,
so that there are no unmeasured confounders. This assumption becomes more reasonable when we
use a large number of covariates as the potential confounding variables instead of one covariate as
considered in Han et al. (2017). Under the unconfoundeness assumption, the CSTE curve can be
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reexpressed as
CSTE(X) = logit(E(Y = 1|X,Z = 1))− logit(E(Y = 0|X,Z = 0)).
Denoting µ(X,Z) = E(Y = 1|X,Z), we model the logarithm of odds ratio as
logit(µ(X,Z)) = g∗1(X) · Z + g∗2(X), (1)
where g∗1(·) and g∗2(·) are unknown single-valued functions of p variables. We see
CSTE(X) = logit(µ(X, 1))− logit(µ(X, 0)) = g∗1(X).
Since g∗1(·) and g∗2(·) are functions of a p-vector, it has the curse of dimensionality when using
nonparametric smoothing techniques to estimate them. For dimensionality reduction, we model
each function as a linear combination of covariates, such that
g∗1(X) = g1(X
>β1), g∗2(X) = g2(X
>β2), (2)
where β1 = (β11, . . . , β1p) and β2 = (β21, . . . , β2p) are two p-vectors of unknown parameters. Then,
substituting (2) into (1) one has
logit(µ(X,Z)) = g1(X
>β1) · Z + g2(X>β2), (3)
with gk as a single-valued function of an index variable for k = 1, 2. The coefficients of the linear
combinations as well as the two unknown functions are chosen to simultaneously maximize the log-
likelihood function of the binomial distribution. The proposed model is a flexible semi-parametric
model and robust against model misspecification, and we call it logistic single index coefficient
model (LSICM). Our LSICM contains the varying coefficient model considered in Han et al. (2017)
as a special case. We have the same form when p = 1. Their model is quite flexible as the
coefficient functions are not required to have a specific parametric structure, but it only captures
the dependence of the response variable Y with one single covariate. This is true when there is
a high degree of association between the response and that covariate. However, in practice, we
often have more than one confounding variables, dimension of which indeed can be high in certain
applications such as biomedical data.
Unlike parametric models, the parameter vectors βk are not identified without further assump-
tions. For the purpose of model identification, we assume that βk for k = 1, 2 belong to the param-
eter space Θ = {β = (β>1 , β>2 )> : ‖βk‖ = 1, βk1 > 0, βk ∈ Rp, k = 1, 2}, where ‖ · ‖ denotes the l2
norm of a vector. Based on the constraint that ‖βk‖ = 1, we eliminate the first component in βk and
obtain the resulting parameter space: Θ−1 = {βk,−1 = (βk2, . . . , βkp)> :
∑
j>1 β
2
kj < 1, k = 1, 2}.
Let βk1 =
√
1−∑j>1 β2kj . The derivative with respect to the coefficients (βk2, . . . , βkp)> can be
easily obtained using the chain rule under the above parameter space. For high-dimensional prob-
lems (with a large number of covariates), p can be much larger than n but only a small number
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of covariates are important or relevant for treatment selection. To this end, we assume that the
number of nonzero elements increases as n increases, but it is much smaller than n. Without loss
of generality, we assume that only the first sk = skn components of βk are non-zeros, i.e., we can
write the true values as βk = (βk1, . . . , βksk , 0, . . . , 0)
>. It is worth noting that Ma and Song (2015)
considered a varying index coefficient model. They studied the low-dimensional case that the num-
ber of covariates is fixed, and the method requires that the response variable be continuous. In our
paper, we allow the number of covariates to be much larger than sample size, which is usually true
for biomedical studies.
3 Estimation and Theory
3.1 Algorithm
In this subsection, we discuss the estimation of model (3). We minimize the negative log-likelihood
function simultaneously with respect to the parameters βk and the functions gk for (k = 1, 2). The
LSICM has the form logit(µ(X,Z)) = g1(X
>β1) ·Z + g2(X>β2). Therefore, we seek the minimizer
of the following negative log-likelihood function given (Xi, Yi, Zi), i = 1, . . . , n:
1
n
n∑
i=1
log{1 + exp(g1(X>i β1)Zi + g2(X>i β2))} −
1
n
n∑
i=1
Yi{g1(X>i β1)Zi + g2(X>i β2)}. (4)
To overcome the problem of high-dimensional covariates, we exploit the sparsity through parameter
regularization. With the sparsity constraint of βk’s, we minimize the following penalized negative
log-likelihood
1
n
n∑
i=1
log{1+exp(g1(X>i β1)Zi+g2(X>i β2))}−
1
n
n∑
i=1
Yi{g1(X>i β1)Zi+g2(X>i β2)}+
2∑
k=1
p∑
j=2
p(βkj , λ),
(5)
where p(·) is a penalty function with a tuning parameter λ that controls the level of sparsity in βk,
k = 1, 2.
The functions gk(·), k = 1, 2, are unspecified and are estimated using B-splines regression. Next,
we introduce the B-splines that will be used to approximate the unknown functions. For k = 1, 2,
we assume the support of gk(·) is [infX(X>βk), supX(X>βk)] = [ak, bk]. Let ak = t0,0 < t1,k <
· · · < tNk,k < bk = tNk+1 be an equally-spaced partition of [ak, bk], called interior knots. Then,
[ak, bk] is divided into subintervals I`,k = [t`,k, t`+1,k), 0 ≤ ` ≤ Nk − 1 and INk = [tNk , tNk+1],
satisfying max0≤`≤Nk |t`+1,k − t`,l|/min0≤`≤Nk |t`+1,k − t`,k| ≤M uniformly in n for some constant
0 < M <∞, where Nk ≡ Nk,n increases with the sample size n. We write the normalized B spline
basis of this space (de Boor, 2001) as Bk(uk) = {B`,k(uk) : 1 ≤ ` ≤ Ln,k}>, where the number
of spline basis functions is Ln,k = Lk = Nk + qk, and qk is the spline order. For computational
convenience, we let Nk = N and qk = q so that Lk = L. In practice, cubic splines with order q = 4
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are often used. By the result in de Boor (2001), the nonparametric function can be approximated
well by a spline function such that gk(X
>βk) ≈ Bk(X>βk)>δk for some δk ∈ RL, k = 1, 2. For
notational simplicity, we write Bk(X
>βk) as B(X>βk). Therefore, the estimates β̂k and δ̂k of the
unknown index parameters βk and the spline coefficients δk are the minimizers of
1
n
n∑
i=1
log{1 + exp(B1(X>i β1)>δ1Zi +B2(X>i β2)>δ2)}
− 1
n
n∑
i=1
Yi{B1(X>i β1)>δ1zi +B2(X>i β2)>δ2}+
2∑
k=1
p∑
j=2
p(βkj , λ),
and they are obtained through an iterative algorithm described as follows.
Step 1: Given βk, the solution of δk is easily obtained. Reexpressing the model gives
logit(µ(X,Z)) ≈ B(X>βk)>δ1Z +B(X>βk)>δ2 =
(
ZB(X>βk)>, B(X>βk)>
)( δ1
δ2
)
.
This can be viewed as a logistic regression using
(
ZB(X>βk)>, B(X>βk)>
)>
as the regressors
without intercept term.
Step 2: Given δk, it remains to find the solution that minimizes (5) with respect to βk. Let β
old
k
and βoldk,−1 be the current estimates for βk and βk,−1, respectively. Let g˜k(X
>βk) = Bk(X>βk)>δk.
We approximate
g˜k(X
>βk) ≈ g˜k(X>βoldk ) + g˜′k(X>βoldk )X>J(βoldk )(βk,−1 − βoldk,−1),
where J(βk) = ∂βk/∂βk,−1 = (−βk,−1/
√
1−‖βk,−1‖22, Ip−1)> is the Jacobian matrix of size p by
p − 1. To obtain the sparse estimates of βk, we carry out a regularized logistic regression with[{Zg˜′1(X>βold1 )J(βold1 )>X}>, {g˜′2(X>βold2 )J(βold2 )>X}>]> as the regressors with a known intercept
term given as
Zg˜1(X
>βold1 ) + g˜2(X
>βold2 )− Zg˜′1(X>βold1 )X>J(βold1 )βold1,−1 − g˜′2(X>βold2 )X>J(βold2 )βold2,−1.
This produces an updated vector βnewk,−1. Then we set β
new
k = (
√
1− ||βnewk,−1||2, (βnewk,−1)>)>, for
k = 1, 2. Steps 1 and 2 are repeated until convergence.
We obtain the initial value of βk through fitting a regularized logistic regression by assuming
that gk(X
>βk) = X>βk. In step 2, we use the coordinate descent algorithm (Breheny and Huang,
2011) to fit the regularized regression. Moreover, we choose to use the non-convex penalties such
as MCP and SCAD which induce nearly unbiased estimators. The MCP (Zhang, 2010) has the
form pγ(t, λ) = λ
∫ t
0 (1− x/(γλ))+dx, γ > 1 and the SCAD (Fan and Li, 2001) penalty is pγ(t, λ) =
λ
∫ t
0 min{1, (γ−x/λ)+/(γ− 1)}dx, γ > 2, where γ is a parameter that controls the concavity of the
penalty functions. In particular, both penalties converge to the L1 penalty as γ → ∞. We put γ
in the subscript to indicate the dependence of these penalty functions on it. In practice, we treat
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γ as a fixed constant. The B-spline basis functions and their derivatives are calculated using the
bsplineS function in R package fda.
From the above algorithm, we obtain the spline estimators of the functions g1(·) and g2(·).
However, the spline estimator only has convergence rates but its asymptotic distribution is not
available in the additive model settings with multiple unknown functions (Stone, 1985), so no
measures of confidence can be assigned to the estimators for conducting statistical inference(Wang
and Yang, 2007). The spline-backfitted kernel (SBK) estimator is designed to overcome this issue
for generalized additive models (Liu et al., 2013), which combines the strengths of kernel and spline
smoothing, is easy to implement and has asymptotic distributions. Denote the SBK estimator of
g1(·) as ĝ1,sbk(·). We obtain ĝ1,sbk(X>0 β̂1) for a new input vector X0 in the following step.
Step 3: Given the spline estimate ĝ2(X
>
i β̂2), the loss criterion for a local linear logistic regression
can be expressed as the following negative quasi-likelihood function:
l(a, b,X) = − 1
n
∑
i
[Yi(aZi + ĝ2(X
>
i β̂2))− log(1 + exp(aZi + ĝ2(X>i β̂2)))]Kh(X>i β̂1 −X>β̂1),
where Kh(·) is a kernel function with bandwidth h. We obtain the estimate â(X0) by minimizing
the above loss function. Then the predicted CSTE value at X0 is
CSTE(X0) ≈ ĝ1,sbk(X>0 β̂1) = â(X0). (6)
Based on the above SBK estimator of CSTE, we can construct a simultaneous confidence band
which is used for optimal treatment selection. The details will be discussed in Section 4.
3.2 Asymptotic Analysis
We first introduce some notations. For any positive sequences {an} and {bn}, let an  bn de-
note limn→∞ anb−1n = C for a constant 0 < C < ∞ and an  bn denote limn→∞ anb−1n = 0.
For a vector a = (a1, . . . , ap)
> ∈ Rp, denote ‖a‖ = (∑pl=1 a2l )1/2 and ‖a‖∞ = maxl |al|. For
a matrix A = (Aij), denote ‖A‖ = max‖ζ‖=1 ‖Aζ‖, ‖A‖∞ = maxi
∑
j |Aij |, and ‖A‖2,∞ =
maxi ||Ai||, where Ai is the ith row. For a symmetric matrix A, let λmin(A) and λmax(A) be
the smallest and largest eigenvalues of A, respectively. We assume that the nonsparsity size
s = max(s1, s2)  n and the dimensionality satisfies log p = O(nα) for some α ∈ (0, 1). De-
note βk1 = (βk1, . . . , βksk)
>, βk1,−1 = (βk2, . . . , βksk)
>, βk2 = (βk(sk+1), . . . , βkp)
>. Then we write
β(1) = (β
>
11, β
>
21)
>, β(2) = (β>12, β>22)>, β(1),−1 = (β>11,−1, β>21,−1)>. Denote the Jacobian matrix as
J(βk1) = ∂βk1/βk1,−1, k = 1, 2, and J(β(1)) = ∂β(1)/∂β(1),−1 = diag(J(β11), J(β21)), which is a
block diagonal matrix. We use the superscript ‘0’ to represent the true values.
Denote the first sk(1 ≤ k ≤ 2) components of Xi as Xi,k1 = (xij , 1 ≤ j ≤ sk)> and the last p−sk
components as Xi,k2 = (xij , sk < j ≤ p)>. Denote S(x) = (1 + e−x)−1 as the sigmoid function.
Then the true expected value of the response given (X,Z) is
E(Y |X,Z) = µ(X,Z) = S(g1(X>β1)Z + g2(X>β2)).
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Define the space M as a collection of functions with finite L2 norm on C × {0, 1} by
M =
{
g(x, z) = g1(x
>β01)z + g2(x
>β02), E{gk(X>β0k)}2 <∞
}
.
For a given random variable U , define its projection onto the space M as
PM(U) = arg min
g∈M
E
[
w0{U − g(X,Z)}2] ,
where w0 = pi0(1− pi0) and pi0 = µ(X,Z). For a vector U = {U1, ..., Ud}, let
PM(U) = {PM(U1), ...,PM(Ud)}>.
Moreover, we define
Ωn =
1
n
n∑
i=1
J(β0(1))
>
(
g′1(X>i,11β
0
11)X˜i,11Zi
g′2(X>i,21β
0
21)X˜i,12
)(
g′1(X>i,11β
0
11)X˜i,11Zi
g′2(X>i,21β
0
21)X˜i,12
)>
J(β0(1)), (7)
where X˜i,kv = Xi,kv − PM(Xi,kv) for k, v = 1, 2, and
Φn =
1
n
n∑
i=1
σ2(Xi, Zi)J(β
0
(1))
>
(
g′1(X>i,11β
0
11)X˜i,11Zi
g′2(X>i,21β
0
21)X˜i,21
)(
g′1(X>i,11β
0
11)X˜i,11Zi
g′2(X>i,21β
0
21)X˜i,21
)>
J(β0(1)),
where σ2(X,Z) = E[{Y − S(g(X,Z))}2|X,Z] .
To establish asymptotic properties, we need the following regularity conditions.
Assumption 1. The penalty function pγ(t, λ) is a non-decreasing symmetric function and concave
on [0,∞). For some constant a > 0, ρ(t) = λ−1pγ(t, λ) is a constant for all t ≥ aλ and ρ(0) = 0.
ρ′(t) exists and is continuous except for a finite number of t and ρ′(0+) = 1.
Assumption 2. For any βk ∈ Θ, gk ∈ Hr for some r > 1, where Hr is the collection of all functions
on [a, b] such that the qth order derivative satisfies the Ho¨lder condition of order γ with r ≡ q + γ,
i.e. for any φ ∈ Hr, there is a C0 ∈ (0,∞) such that |φ(qt)(u1)−φ(q)(u2)| ≤ C0|u1−u2|γ for any a ≤
u1, u2 ≤ b.
Assumption 3. For 1 ≤ j ≤ sk, E(X2+2(κ+1)j ) ≤ Cκ,k for some constant κ ∈ (0, 1). For
sk ≤ j ≤ p− sk, E(|Xj |2+%) ≤ C%,k, for some % > (8/3)(1− α)−1 − 2 and % ≥ 2.
Assumption 4. There exist c, c′, ck ∈ (0,∞) such that λmin(Ωn) ≥ c, λmin(Φn) ≥ c′ almost surely,
and ‖E(X˜k2X˜>k1)‖2,∞ ≤ ck, where X˜kv = Xkv − PM(Xkv), for k, v = 1, 2.
Assumption 5. Let wn = 2
−1 min{|β0kj | : 2 ≤ j ≤ s, k = 1, 2}/2. Assume that max((s/n)1/2, L1−r+
L3/2nα/2−1/2) λ wn.
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Assumption 1 is a typical condition on the penalty function, see Fan and Lv (2011). The concave
penalties such as SCAD and MCP satisfy Assumption 1. Assumption 2 is a typical smoothness
condition on the unknown nonparametric function, see for instance Condition (C3) in Ma and He
(2016). Assumption 3 is required for the covariates, see Condition (A5) in Ma and Yang (2011).
Moreover, the design matrix needs to satisfy Assumption 4. A similar condition can be found in Fan
and Lv (2011). Assumption 5 assumes that half of the minimum nonzero signal in β0k is bounded
by some thresholding value, which is allowed to go to zero as n → ∞. This assumption is needed
for variable selection consistency established in Theorem 1.
Denote β−1 = (β>11,−1, β>12, β>21,−1, β>22)>. Let s = max(s1, s2). Theorem 1 establishes the
consistency for the parameters in model (3).
Theorem 1. Under Assumptions (A1)-(A5), and α ∈ (0, (2r − 5/2)/(2r − 1)), L1−rs1/2 = o(1),
nα−1(L3 + s) = o(1), n1/2L1−2r = o(1), log(n)(s1/2 + L1/2)L3/2n−1/2 = o(1), there exists a strict
local minimizer β̂−1 = (β̂>11,−1, β̂>12, β̂>21,−1, β̂>22)> of the loss function given in (5) such that β̂k2 = 0
for 1 ≤ k ≤ 2 with probability approaching 1 as n→∞, and ‖β̂−1 − β0−1‖ = Op(
√
s/n).
Remark. Based on the assumption given in Theorem 1, the number of spline basis functions
needs to satisfy n1/{2(2r−1)}  L min{n1/4{log(n)}−1, n(1−α)/3}.
The following Theorem presents the convergence rate for the spline estimator of the unknown
functions.
Theorem 2. Under conditions given in Theorem 1, we have n−1
∑n
i=1{ĝk(X>i β̂k)−gk(X>i β0k)}2 =
Op(L
−2r + L/n+ s/n), for k = 1, 2.
To estimate the simultaneous confidence band, we need the following assumptions, see Assump-
tions (A4) and (A6) in Zheng et al. (2016).
Assumption 6. Let r = 2. The kernel function K is symmetric probability density function sup-
ported on [−1, 1] and has bounded derivative. The bandwidth h satisfies h = hn = o(n−1/5(log n)−1/5)
and h−1 = O(n1/5(log n)δ) for some constant δ > 1/5.
Assumption 7. The joint density of X>β01 and X>β02 is a bounded and continuous function. The
marginal probability density functions have continuous derivatives and the same bound as the joint
density.
We borrow some notations in Zheng et al. (2016):
σ2(u) = E[µ(u, Z)(1− µ(u, Z))|Z = 1], D(u) = f(u)σ2(u), v2(u) = ||K||22f(u)σ2(u), (8)
where µ(u, Z) = S(g1(u)Z + g2(X
>β02)) and f(u) is the density function of X>β01 . Define the
quantile function
Qh(α) = ah + a
−1
h [log(
√
CK/(2pi))− log(− log
√
1− α)]
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for any α ∈ (0, 1), where ah =
√−2 log h and CK = ||K ′||22/||K||22. Without loss of generosity,
assume X>β01 is in the range [0, 1] and let C be a set of X such that C = {X : X>β01 ∈
[h, 1−h], X ∈ Rp}. Theorem 3 is an adaptation from Theorem 1 in Zheng et al. (2016). It provides
a method to construct the simultaneous confidence band for g1.
Theorem 3. Under Assumptions 1-7, and α ∈ (0, 2/5), sn−1/10(log n)−3/5 = O(1) and n1/5 
L min{n1/4{log(n)}−1, n(1−α)/3}, we have
lim
n→∞P
(
sup
X∈C
∣∣∣∣∣ ĝ1,sbk(X>β̂1)− g1(X>β01)σn(X>β̂1)
∣∣∣∣∣ ≤ Qh(α)
)
= 1− α,
where σn(X
>β1) = n−0.5h−0.5v(X>β1)/D(X>β1).
Remark. For details of implementations of kernel and spline estimation for functions in (8),
we refer to Zheng et al. (2016). As suggested in Zheng et al. (2016), we use a data-driven under
smoothing bandwidth h = hopt(log n)
−1/4 and hopt is given in Zheng et al. (2016). We let the
number of spline interior knots be
⌊
n1/5(log n)
⌋
+ 1. The 100(1 − α)% simultaneous confidence
band for g1(X
>β01) is ĝ1,sbk(X>β̂1)± σn(X>β̂1)Qh(α).
4 Treatment Selection via Confidence Bands
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Figure 1: A simulated example, demonstrating CSTE estimation, confidence bands and cutoff
points. The solid curve is point estimation of CSTE function. The dashed curves are corresponding
confidence bands of the CSTE curve. Four vertical dash lines indicate the locations of cutoff points.
In this section, attention is focused on making individualized treatment decision rule for patients.
We provide an example to illustrate how to select the optimal treatment based on CSTE curve and
its confidence bands. The goal of treatment selection is to find which group of patients will benefit
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from new treatment based on their covariates. By the definition of CSTE curve, if we assume
that the outcome of interest is death, the CSTE curve is the odds ratio of the treatment effect in
reducing the probability of death. That is, a positive CSTE(X) value means that the patients will
not benefit from new treatment since they may have a higher death rate than patients who receive
old treatment. We define the cutoff points as the places where the upper and lower confidence
intervals equal to 0, i.e.
Sl = {v ∈ R : gˆl(v) = 0} and Su = {v ∈ R : gˆu(v) = 0}.
Based on these cutoff points, we are able to identify the regions with the positive and negative
values of CSTE(X), respectively, so that it will guide us to select the best treatment for a future
patient. To summarize, this treatment selection method consists of the following steps:
Step 1. Estimate CSTE curve gˆ1(X
>βˆ1) and the corresponding confidence bands.
Step 2. Identify the cutoff points and the regions of positive and negative values for gˆ1(X
>βˆ1).
Step 3. Select optimal treatment for a new patient based on the values of its baseline covariates.
We use the following example to illustrate the method of using the simultaneous confidence
bands to select optimal treatment for patients. We assume that X>βˆ1 has a range of (−4, 2). In
Figure 1, the solid line represents a CSTE curve and dashed lines above and below the curve are
the corresponding 95% confidence bands. We assume that the outcome variable Y is the indicator
of death. As shown in Figure 1, the CSTE is decreasing when the value of X>βˆ1 is from -4 to
-1.6 and it is increasing when the value of X>βˆ1 is from -1.6 to 2. In general, when the X>βˆ1
value of a patient is within the range of (-4,-1.6), a larger value implies that the patient more likely
benefits from the new treatment than from the old treatment. On the other hand, if the patient’s
X>βˆ1 value falls into (-1.6,2), the new treatment is more beneficial when a smaller value of X>βˆ1 is
observed. Moreover, the results in Figure 1 also imply that we are 95% confident that a new patient
with the X>βˆ1 value falling into the region [−4, a] or [d, 2] will benefit from the old treatment, since
the lower bands are all above zero in this region. If X>0 βˆ1 falls into region [b, c], then we have 95%
confidence that the patient should receive the new treatment, as the upper bands are all below zero
in this region. For the intervals [a, b] and [c, d], zero is covered in the confidence band indicating
that there is no significant difference between the effects of the new and old treatments. Han et al.
(2017) define a modified version of the CSTE curve using the quantile of the covariate to compare
covariates’ capacities for predicting responses to a treatment. Then they use the ”best” covariate
as a guidance to select treatment. This may be time-consuming when there is a large number
of covariates. Our method selects relevant covariates automatically in the estimation procedure
and combines information from all covariates through a weighted combination of those covariates
with the weights estimated from the data. The weight reflects how important the corresponding
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covariate is for predicting the response. As a result, our method is more convenient and flexible in
selecting optimal treatment.
5 Simulation Study
In this section, we investigate the finite-sample performance of our proposed method via simulated
datasets. We run all simulations in R in a linux cluster. We consider three examples:
Example 1. logit(µ(X,Z)) = X>β1(1−X>β1)Z + exp(X>β2).
Example 2. logit(µ(X,Z)) = (X>β2)2Z + sin(piX>β2/2).
Example 3. logit(µ(X,Z)) = − exp(X>β1)Z/1.5 + (X>β2)2.
The simulated data are generated as follows: the outcome Y is sampled from a binomial distri-
bution with probability of success equals to µ(x, z); the covariates X are generated from a truncated
multivariate normal distribution with mean vector 0, covariance matrix with Σij = 0.5
|i−j|, and each
covariate is truncated by (−2, 2); the binary scale covariate Z is sampled from Binomial(1, 0.5),
which means that each subject is randomly assigned to either control or treatment group. We
set β1 = (1, 1, 1, 0, . . . , 0)
′/
√
3, β2 = (1,−2, 0, . . . , 0)′/
√
5, p = 10, 50, 100, 500, and sample size
n = 500, 750, 1000. For each pair of n and p, we repeat the simulations J = 300 times.
To obtain sparse estimates of βk for high-dimensional cases, we choose SCAD as the penalty
function and let γ = 3.7 (Fan and Li, 2001). The optimal tuning parameter λ is chosen from a ge-
ometrically increasing sequence of 30 parameters by minimizing the modified Bayesian information
criterion (Wang et al., 2009): BICλ = −2 · log(Loss) + dfλ · log(n) · C(p), where Loss is the loss
function in (5), dfλ is the number of non-zero elements in βk, C(p) = C(p) = log log(p).
Denote t1, . . . , t200 as 200 equally spaced grid points on the range of ηˆ1 = X
>βˆ1. Then we
evaluate the following metrics for non-parametric function g1(·): mean square error; mean absolute
error; the average coverage probability of the simultaneous confidence bands. For variable selection,
we compute the average number of parameters that are incorrectly estimated to be non-zero, the
average number of parameters that are incorrectly estimated as zero; the proportions that all
relevant covariates are correctly selected and the proportions that some relevant covariates are not
selected.
We define that the oracle estimator of g1(·) is obtained when the true indexes of non-zero
components in βks are given. The results are summarized in Table 1. We see that the coverage
probabilities are slightly less than 95% but close to 90% when the sample size is 750. When the
sample is 1000, the empirical coverage is close to the nominal 95% confidence level. The mean
square error and mean absolute error also decrease as sample size n increases. This shows that
the estimates of confidence bands become more accurate as the sample size increases. The model
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selection results are summarized in Table 2. The false positive and false negative are decreasing
when n increases. The above studies evidently indicate the reliability of our methodology. It
ensures their applications for the real data example in the following section.
Model 1 Model 2 Model 3
(n, p) MSE MAE CP MSE MAE CP MSE MAE CP
(500, Oracle) 0.230 0.364 0.880 0.217 0.336 0.861 0.389 0.400 0.840
(750, Oracle) 0.125 0.276 0.925 0.113 0.251 0.905 0.143 0.268 0.905
(1000, Oracle) 0.095 0.23 0.947 0.088 0.230 0.935 0.083 0.220 0.940
(500, 10) 0.280 0.494 0.874 0.325 0.428 0.889 0.405 0.461 0.858
(750, 10) 0.169 0.318 0.897 0.151 0.293 0.924 0.329 0.472 0.885
(1000, 10) 0.112 0.258 0.939 0.095 0.243 0.929 0.099 0.241 0.931
(500, 50) 0.530 0.461 0.871 0.506 0.576 0.870 0.679 0.621 0.863
(750, 50) 0.258 0.371 0.930 0.331 0.426 0.903 0.280 0.393 0.920
(1000, 50) 0.100 0.248 0.957 0.129 0.280 0.955 0.099 0.242 0.959
(500, 100) 0.698 0.594 0.836 0.525 0.566 0.826 0.640 0.660 0.862
(750, 100) 0.153 0.305 0.906 0.452 0.477 0.896 0.141 0.291 0.907
(1000, 100) 0.108 0.230 0.947 0.188 0.338 0.920 0.093 0.237 0.940
(500, 500) 0.718 0.789 0.826 0.642 0.777 0.835 0.683 0.519 0.831
(750, 500) 0.413 0.503 0.857 0.434 0.453 0.860 0.524 0.444 0.854
(1000, 500) 0.123 0.249 0.930 0.174 0.319 0.925 0.143 0.287 0.912
Table 1: Simulation results. Oracle estimator is obtained when true index sets are given. True
functions are x(1−x), x2,− exp(x)/1.5. MSE, MAE, CP represent mean square error, mean absolute
error and coverage probability of the simultaneous confidence bands, respectively.
6 A Real Data Example
In this section, we present and discuss the results of applying the procedure described in previous
sections to a real data set. We illustrate the applications of the CSTE curve in a real-world example
and provide some insight into the interpretation of the results. The goal is to analyze the effect
of Zhengtianwan in the treatment of migraines. This is a multicenter, randomized, double-blind,
placebo-controlled trial on the effectiveness of Zhengtian pill on treating patients with migraines. A
migraine is a common neurological disorder characterized by recurrent headache attacks. Migraine
treatment involves acute and prophylactic therapy. The objective of this study is to evaluate the
efficacy and safety of Zhengtian Pill for migraine prophylaxis. Zhengtian Pill, a Chinese Patented
Medicine approved by the State Food and Drug Administration of China in 1987, has been used in
clinical practice for more than 20 years in China to stimulate blood circulation, dredge collaterals,
alleviate pains, and nourish the liver. To evaluate the effectiveness of Zhengtian Pill in preventing
14
Model 1 Model 2 Model 3
(n, p) FPR FNR C IC FPR FNR C IC FPR FNR C IC
(500, 10) 0.282 0.025 0.885 0.115 0.274 0.019 0.904 0.095 0.381 0.015 0.909 0.090
(750, 10) 0.206 0.008 0.956 0.043 0.170 0.007 0.960 0.039 0.280 0.018 0.941 0.058
(1000, 10) 0.162 0.000 1.000 0.000 0.110 0.005 0.994 0.005 0.217 0.002 0.989 0.010
(500, 50) 0.271 0.042 0.785 0.214 0.172 0.181 0.564 0.435 0.165 0.236 0.535 0.465
(750, 50) 0.108 0.041 0.823 0.176 0.178 0.025 0.892 0.107 0.094 0.125 0.563 0.436
(1000, 50) 0.070 0.009 0.952 0.047 0.111 0.005 0.975 0.025 0.082 0.065 0.788 0.211
(500, 100) 0.063 0.093 0.625 0.375 0.107 0.084 0.605 0.395 0.093 0.087 0.670 0.330
(750, 100) 0.055 0.065 0.703 0.296 0.098 0.044 0.688 0.311 0.040 0.106 0.681 0.318
(1000, 100) 0.031 0.032 0.845 0.154 0.053 0.037 0.830 0.170 0.021 0.061 0.803 0.196
(500, 500) 0.114 0.138 0.471 0.519 0.119 0.164 0.223 0.777 0.104 0.166 0.243 0.757
(750, 500) 0.974 0.096 0.540 0.460 0.069 0.138 0.294 0.706 0.059 0.132 0.302 0.698
(1000, 500) 0.030 0.062 0.609 0.391 0.039 0.102 0.413 0.587 0.049 0.094 0.449 0.551
Table 2: Model selection results. FP(false positive): zero is estimated as non-zero; FN(false neg-
ative): non-zero is estimated as zero; C(correctly selected): all relevant covariates are selected;
IC(incorrectly selected): some relevant covariates are not selected.
the onset of migraine attacks, a large-scale, randomized, prospective clinical study was conducted.
Eligible patients were monitored during a baseline period of four weeks, during which the headache
characteristics were recorded as baseline data. In this period, any use of migraine preventive
medications was prohibited. After the baseline period, a 12-week treatment period and four-week
follow-up period were carried out. Patients were requested to keep a headache diary throughout
the whole study period, from which investigators were able to extract detailed information of
migraine attacks including migraine days, frequency, duration, and intensity as well as the use of
acute medication during the study period. The outcome measures were evaluated at 4, 8, and 12
weeks, and during the follow-up period. The patients who met the inclusion criteria were randomly
assigned into the experimental group and control group in a 1:1 ratio using a computer-generated
stochastic system.
In our analysis, the response variable Y is a binary outcome indicating if the number of days
that headaches occur has decreased 8 weeks after patients were treated. Z is another indicator:
Z = 1 means the subject is assigned in the experimental group; Z = 0 means in the control group.
The covariates x1 to x3 are gender (0 for male, 1 for female), height and body weight, x4 to x12 are
overall scores for TCM symptoms Huozheng, Fengzheng, Xueyu, Tanshi, Qixu, Yuzheng, Xuexu,
Yinxu, Yangxu at week 0, respectively. All covariates are centered and standardized as input. We
have 204 observations where 99 are in the experimental group and 105 are in the control group. The
purpose of this exercise is to model the odds ratio as a function of those covariates. The number of
covariates p = 12 might be regarded as small, so we estimate the CSTE curve using the algorithm
in Section 3.1 with and without model selection. We use SCAD as our penalty function and the
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optimal tuning parameter is selected via the modified BIC criterion. The corresponding confidence
bands for the CSTE curve are calculated. The results are not intended as definitive analyses of
these data.
Table 3 summarizes the point estimates of β1 and the corresponding standard errors. Figure 2
shows two estimated CSTE curve and their confidence bands: (a) using all 12 variables; (b) using all
variables except x7 and x8 (not selected). To aid in interpretation for each covariate, we depict each
covariate versus g1 where other covariates are projected onto their mean values in Figure 3. As we
can see, Huozheng has a monotonic dependence on the CSTE, but the corresponding relationships
for other overall scores are highly nonlinear; most of them have a quadratic appearance. On the
basis of these Figures, we can conclude that the odds ratio does depend on the linear combination
of the covariates in a nonlinear manner.
If all variables are used to estimate the curve, the two cutoff points are c1 = −0.502, c2 = 2.182.
The estimates of the overall rating of biomarker values are x>βˆ1 where the majority of the points
(> 95%) fall into the interval (−1.2, 5). Two cutoff points divide this interval into three parts.
Since the response variable y = 1 represents headache improves after 8 weeks treatment, higher
CSTE value means the patient is more likely benefited from the treatment. Suppose a new patient
with biomarker value x0, then when x
>
0 βˆ1 falls into [−1.2, c1] and [c2, 5], the treatment does not
have significant effect, but if it falls into (c1, c2), then this treatment can improve the headache of
this patient. In the Zhengtianwan data, there are 37.7% of patients fall into the interval. On the
other hand, when x7, x8 are removed from the model, we obtain a new estimate β1,ms. As we can
see from Figure 2 (b), the positive region of the CSTE curve becomes wider than (a) where the two
cutoff points become -0.811 and 2.366. The majority of x>βˆ1,ms falls into −(2.5, 5). When x>0 βˆ1,ms
is in the range of [−0.811, 2.366], the patient should receive Zhengtianwan treatment and 50.98%
of all patients in the training dataset fall into this interval.
Variable Gender Height Weight Huozheng Fengzheng Xueyu Tanshi Qixu Yuzheng Xuexu Yinxu Yangxu
β1
0.88 0.10 -0.04 -0.06 0.08 -0.09 -0.08 0.04 0.18 -0.24 0.30 -0.03
(0.23) (0.01) (0.01) (0.03) (0.02) (0.01) (0.03) (0.11) (0.04) (0.05) (0.07) (0.02)
Penalizd β1
0.70 0.11 -0.05 -0.04 0.14 -0.15 0.00 0.00 0.21 -0.38 0.49 -0.14
(0.31) (0.02) (0.01) (0.02) (0.03) (0.01) (0.00) (0.00) (0.05) (0.07) (0.09) (0.06)
Table 3: Estimates of β1 and the corresponding standard errors(in parentheses). First row: using
the unpenalized model; second row: using the penalized model.
7 Discussion
Both the simulation and real-world studies in Sections 5 and 6 suggest that the modeling procedure
for CSTE curve can successfully detect and model complicated non-linear relationships between bi-
nary response and high-dimensional covariates. In practice, the non-linear dependencies we suggest
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Figure 2: Real data example. Red curve is the CSTE curve; blue dashed curves are the confidence
bands. (a) two cutoff points are -0.502 and 2.182; (b) two cutoff points are -0.811 and 2.366.
are not characteristic of all situations. We adapt the spline-backfitted kernel smoothing to construct
the simultaneous confidence bands for the non-linear functions to choose the optimal treatment.
Moreover, the confidence bands can be used to verify the presence of non-linear relationships as
well.
Our model is motivated by the desire to provide an individualized decision rule for patients
along with the ability to deal with high-dimensional covariates when the outcome is binary. The
semi-parametric modeling approach can be viewed as a generalization of the CSTE curve with one
covariate proposed in Han et al. (2017) in the sense that the odds ratio depends on a weighted
linear combination of all covariates. Although we consider a single decision with two treatment
options, our model can be readily generalized to multiple treatment arms.
Supplementary material
Supplementary material includes the technical proofs for all the theoretical results.
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Figure 3: Plot one covariate against CSTE curve with other covariates fixed on their mean values.
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